A Novel Bifunctional Fusion Protein, Vunakizumab-IL22, for Protection Against Pulmonary Immune Injury Caused by Influenza Virus

A Novel Bifunctional Fusion Protein, Vunakizumab-IL22, for Protection Against Pulmonary Immune Injury Caused by Influenza Virus

Influenza A virus an infection is often related to acute lung harm, which is often characterised by tracheal mucosal barrier harm and an interleukin 17A (IL-17A)-mediated inflammatory response in lung tissues. Though concentrating on IL-17A has been confirmed to be useful for attenuating irritation round lung cells, it nonetheless has a restricted impact on pulmonary…

Read More